Cardiac stem cells: Current knowledge and future prospects

doi:10.4252/wjsc.v14.i1.1

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12168)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-3) series.

Item

Count

PDF

492

WORD

145

HTML

8652

Figures (1-6)

303

Tables (1-3)

286

Sum=9878

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

246

Download

732

Sum=978

Publishing Process of This Article

Item

Count

Browse

359

Download

953

Sum=1312

Jan 26, 2022 (publication date) through Nov 30, 2024

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Stem Cells. Jan 26, 2022; 14(1): 1-40
Published online Jan 26, 2022. doi: 10.4252/wjsc.v14.i1.1

Table 3 Ongoing and future expected clinical trials

Study name, NCT number	Year of study start	Study phase	Cardiovascular disease	Number of patients	Type of cardiac cells	Route of delivery
Regress-HFpEF, 02941705	2017	II	Symptomatic hypertensive heart disease induced HFpEF	40	Allogeneic CDCs	IC
APOLLON trial, 02781922	2016	III	HLHS	40	Autologous CSCs	IC
CHILD, 03406884	2019	I	HLHS	32	Autologous c-KIT⁺ cells	IM
ALPHA, 03145298	2017	I	PAH	26	Allogeneic CDC	IV
TAC-HFT-II, 02503280	2025	I/II	IHF	0 enrollment until now	Autologous combination of MSCs and CSCs	Trans endocardial Injection

CSC: Cardiac stem cell; HFpEF: Heart failure with preserved ejection fraction; HLHS: Hypoplastic left heart syndrome; IC: Intracardiac; IHF: Ischemic heart failure; IM: Intramyocardial; IV: Intravenous; NCT: National clinical trial; PAH: Pulmonary atrial hypertension.

Citation: Mehanna RA, Essawy MM, Barkat MA, Awaad AK, Thabet EH, Hamed HA, Elkafrawy H, Khalil NA, Sallam A, Kholief MA, Ibrahim SS, Mourad GM. Cardiac stem cells: Current knowledge and future prospects. World J Stem Cells 2022; 14(1): 1-40
URL: https://www.wjgnet.com/1948-0210/full/v14/i1/1.htm
DOI: https://dx.doi.org/10.4252/wjsc.v14.i1.1